Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.
- Published In:
- Life sciences, 58(20), 1777-84 (1996)
- Authors:
- Dorr, R T, Lines, R, Levine, N, Brooks, C, Xiang, L, Hruby, V J, Hadley, M E
- Database ID:
- RPEP-00359
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-00359APA
Dorr, R T; Lines, R; Levine, N; Brooks, C; Xiang, L; Hruby, V J; Hadley, M E. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.. Life sciences, 58(20), 1777-84.
MLA
Dorr, R T, et al. "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.." Life sciences, 1996.
RethinkPeptides
RethinkPeptides Research Database. "Evaluation of melanotan-II, a superpotent cyclic melanotropi..." RPEP-00359. Retrieved from https://rethinkpeptides.com/research/dorr-1996-evaluation-of-melanotanii-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.